InsiderDB

Lobbying disclosures · Lobbying report

BMY: second_quarter 2026 lobbying report

Issues related to prescription drugs Issues related to prescription drugs; Issues related to Senate Finance Dear Colleague process; Issues related to the Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the Orphan Cures Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; S. 3019, No Big Blockbuster Bailouts Act (NOBBBA)

Follow BMY
Became public
Jul 20, 2026, 1:59 PM EDT
Event / period date
Not stated
Collected
Nov 10, 2026, 11:10 AM EST

Why this is connected

Legal-name match: BRISTOL-MYERS SQUIBB COMPANY is BRISTOL MYERS SQUIBB CO (https://www.sec.gov/Archives/edgar/data/14272/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).

Reported lobbying amounts

Income: $60,000.00

These are different reporting measures. They are not added together or treated as spending on one particular bill.

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/ce793bb9-f7de-4ee0-ab86-79ed48a1b63a/","filing_uuid":"ce793bb9-f7de-4ee0-ab86-79ed48a1b63a","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/ce793bb9-f7de-4ee0-ab86-79ed48a1b63a/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Tracy Spicer","dt_posted":"2026-07-20T13:59:52-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"401 9th St. NW","registrant_address_2":"Suite 720","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":72111,"url":"https://lda.gov/api/v1/registrants/72111/","house_registrant_id":35940,"name":"AVENUE SOLUTIONS","description":"Government representation","address_1":"401 9th St. NW","address_2":"Suite 720","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"AMY TEJRAL","contact_telephone":"+1 202-347-9848","dt_updated":"2026-07-30T13:56:38.410932-04:00"},"client":{"id":71374,"url":"https://lda.gov/api/v1/clients/71374/","client_id":71374,"name":"BRISTOL-MYERS SQUIBB COMPANY","general_description":"Biopharmaceutical Company","client_government_entity":null,"client_self_select":false,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2026-01-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to prescription drugs","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":23462,"prefix":null,"prefix_display":null,"first_name":"TRACY","nickname":null,"middle_name":null,"last_name":"SPICER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149107,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"FUENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to prescription drugs; Issues related to Senate Finance Dear Colleague process; Issues related to the Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the Orphan Cures Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; S. 3019, No Big Blockbuster Bailouts Act (NOBBBA)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":23462,"prefix":null,"prefix_display":null,"first_name":"TRACY","nickname":null,"middle_name":null,"last_name":"SPICER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149107,"prefix":null,"prefix_display":null,"first_name":"MATTHEW","nickname":null,"middle_name":null,"last_name":"FUENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Congressional trading in BMY

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.